From Health Canada:
Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian healthcare professionals of important new safety information concerning RITUXAN (rituximab).
RITUXAN is authorized in Canada for the treatment of non-Hodgkin’s lymphoma (a cancer of the lymph nodes) and rheumatoid arthritis (an inflammatory disease of the joints).
For health care professionals
For the public
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment